Pipeline Flex与Vantage联合Shield技术治疗颅内动脉瘤的多中心经验
该多中心回顾性研究纳入2017至2023年连续接受Pipeline Vantage或Pipeline Flex with Shield Technology(PFS)治疗的141例患者共147个颅内动脉瘤,评估其临床安全性与疗效。结果显示所有手术技术成功,主要神经不良事件发生率为4.2%(6/144,均为缺血性卒中),平均随访11个月时完全闭塞率为75.9%(85/112)。结论认为表面修饰的Pipeline血流导向装置具有高可行性、手术安全性和疗效。
要点
- 主要神经不良事件发生率为4.2%(6/144),均为缺血性卒中,其中2例(1.4%)死亡,无出血并发症。
- 平均随访11个月时完全闭塞率为75.9%(85/112),入口残余13.4%(15/112),动脉瘤残余10.7%(12/112)。
核心结论
- 表面修饰的Pipeline血流导向装置(Pipeline Vantage和PFS)在颅内动脉瘤治疗中表现出高可行性、手术安全性和疗效。
研究设计与样本
- 多中心回顾性研究,连续纳入2017至2023年接受治疗的141例患者,共144次手术(112次Pipeline Vantage,32次PFS),治疗147个动脉瘤,平均大小8.0 mm(SD 5.9);安全性终点为住院期间手术及术后主要神经事件,疗效终点为末次随访完全闭塞率。
关键影像表现/征象
- 动脉瘤特征:11%为破裂动脉瘤,16%位于后循环,18%为非囊状形态。
- 所有手术技术成功,平均植入1.2枚装置;20/144(13.9%)次手术需球囊血管成形术。
- 末次随访时85/112(75.9%)动脉瘤完全闭塞,15/112(13.4%)见入口残余,12/112(10.7%)见动脉瘤残余。
诊断标准与关键数值
- 安全性终点:住院期间手术及术后主要神经事件发生率为6/144(4.2%),均为缺血性卒中,其中2例(1.4%)死亡,无出血并发症。
- 疗效终点:末次随访完全闭塞率为85/112(75.9%),入口残余为15/112(13.4%),动脉瘤残余为12/112(10.7%)。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: The Pipeline Embolization Device is a safe and effective treatment option for intracranial aneurysms. The newer Pipeline generations have received structural refinements and a surface modification to improve deliverability, procedural safety, and angiographic outcomes. This multicenter study evaluated the clinical safety and efficacy of the 2 surface-modified Pipeline iterations, Pipeline Vantage and Pipeline Flex with Shield Technology (PFS).
MATERIALS AND METHODS: Consecutive patients treated between 2017 and 2023 were retrospectively reviewed for aneurysm characteristics, procedural details, complications, and angiographic outcomes. The safety end point was the rate of procedural and postprocedural major neurologic events occurring during the hospital stay. The efficacy end point was the rate of complete occlusion at last follow-up.
RESULTS: One hundred forty-one patients underwent 112 Pipeline Vantage procedures and 32 PFS procedures for 147 aneurysms with a mean size of 8.0 (SD, 5.9) mm (11% ruptured, 16% posterior circulation, 18% nonsaccular morphology). All procedures were technically successful with a mean of 1.2 devices implanted. Balloon angioplasty was required in 20/144 (13.9%) procedures. Major neurologic adverse events occurred in 6/144 (4.2%) procedures (all ischemic stroke), resulting in death in 2 (1.4%) patients. There were no hemorrhagic complications. At a mean of 11 months, complete occlusion was achieved in 85/112 (75.9%) aneurysms, 15/112 (13.4%) had an entry remnant, and 12/112 (10.7%) had an aneurysm remnant.
CONCLUSIONS: The results demonstrate high feasibility, procedural safety, and efficacy of the surface-modified Pipeline flow diverters.
引用
- Goertz L, Hohenstatt S, Vollherbst DF, et al. Multicenter Experience with the Pipeline Flex and Vantage with Shield Technology for Intracranial Aneurysm Treatment. AJNR Am J Neuroradiol. 2024. PMID: 39122468. doi:10.3174/ajnr.A8352
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。